Stockscreener 앱 받기
0.2491
1.15%
-0.0029
전일 마감가:
$0.252
열려 있는:
$0.251
하루 거래량:
344.58K
Relative Volume:
0.37
시가총액:
$11.48M
수익:
-
순이익/손실:
$-37.75M
주가수익비율:
-0.0766
EPS:
-3.25
순현금흐름:
$-30.91M
1주 성능:
+1.67%
1개월 성능:
-20.26%
6개월 성능:
-84.23%
1년 성능:
-91.86%
1일 변동 폭
$0.242
$0.2584
1주일 범위
$0.2401
$0.274
52주 변동 폭
$0.224
$3.42
Cellectar Biosciences Inc Stock (CLRB) Company Profile
명칭
Cellectar Biosciences Inc
전화
(608) 441-8120
주소
100 CAMPUS DRIVE, FLORHAM PARK, NJ
CLRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2491 | 11.29M | 0 | -37.75M | -30.91M | -3.25 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 재개 | Ladenburg Thalmann | Buy |
| 2020-07-01 | 개시 | Oppenheimer | Outperform |
| 2020-01-21 | 재개 | ROTH Capital | Buy |
| 2019-09-13 | 개시 | ROTH Capital | Buy |
| 2016-12-21 | 개시 | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives - MSN
Analysts Update Their Estimates For Cellectar Biosciences Inc - Stocksregister
Cellectar Biosciences’ (CLRB) “Hold” Rating Reiterated at Maxim Group - Defense World
Roth Capital Brokers Increase Earnings Estimates for CLRB - Defense World
Cellectar Biosciences Earnings Call: Progress Amid Challenges - TipRanks
Cellectar Biosciences (CLRB) Downgraded to 'Hold' by Maxim Group - GuruFocus
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (CLRB) Downgraded Amid Strategic Uncertain - GuruFocus
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Cellectar Biosciences Reports Q1 2025 Financials and Strategic Plans - TipRanks
Transcript : Cellectar Biosciences, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Cellectar Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CLRB Focuses on Advancing Radiotherapeutic Developments Amidst R - GuruFocus
Cellectar Biosciences Reports First Quarter 2025 Financial Resul - GuruFocus
Cellectar Biosciences, Inc. SEC 10-Q Report - TradingView
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Cellectar Biosciences (CLRB) Expected to Announce Earnings on Tuesday - Defense World
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. to Report Q1 2025 Financial Results and Corporate Update on May 13, 2025 - Nasdaq
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 - GlobeNewswire
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on ... - Bluefield Daily Telegraph
JPMorgan Chase & Co. Has $55,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated by Analysts at StockNews.com - Defense World
It makes sense and dollars to buy Cellectar Biosciences Inc (CLRB) stock - Sete News
Cellectar Biosciences (CLRB) Considers Strategic Options to Enha - GuruFocus
Cellectar Announces Plan to Explore Strategic Alternatives | CLR - GuruFocus
Cellectar Biosciences Inc (CLRB) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Checking in on Cellectar Biosciences Inc (CLRB) after recent insiders movement - knoxdaily.com
CLRB’s earnings estimates: Are they on track to meet expectations? - uspostnews.com
Cellectar explores strategic options to enhance shareholder value - Investing.com
Cellectar Announces Plan to Explore Strategic Alternatives - The Manila Times
Cellectar Explores Sale Options: Promising Cancer Drug Pipeline Attracts Strategic Review - Stock Titan
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
Financial Metrics Unveiled: Cellectar Biosciences Inc (CLRB)’s Key Ratios in the Spotlight - DWinneX
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Analysis - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences Enhances CEO and COO Severance Benefits - TipRanks
What is Roth Capital’s Estimate for CLRB FY2029 Earnings? - Defense World
Earnings call transcript: Cellectar Biosciences Q4 2024 sees restructuring amid losses - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Inc (CLRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):